Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches
Executive Summary
Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market
You may also be interested in...
DTC Limits Best Countered By Free Speech, Not Public Health, Arguments
Limits on direct-to-consumer advertising which have been proposed in pending drug safety legislation may best be defeated by constitutional, rather than public health, arguments, Jim Davidson, president of the public policy advisory firm Davidson & Company, said
DTC Limits Best Countered By Free Speech, Not Public Health, Arguments
Limits on direct-to-consumer advertising which have been proposed in pending drug safety legislation may best be defeated by constitutional, rather than public health, arguments, Jim Davidson, president of the public policy advisory firm Davidson & Company, said
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products